NASDAQ:ASNS - Arsanis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.03 -0.14 (-4.42 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$3.03
Today's Range$2.98 - $3.29
52-Week Range$2.94 - $28.69
Volume207,910 shs
Average Volume210,738 shs
Market Capitalization$45.31 million
P/E Ratio-0.19
Dividend YieldN/A
BetaN/A
Arsanis logoArsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive ASNS News and Ratings via Email

Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASNS
CUSIPN/A
Phone781-819-5704

Debt

Debt-to-Equity Ratio0.20
Current Ratio7.38
Quick Ratio7.38

Price-To-Earnings

Trailing P/E Ratio-0.19
Forward P/E Ratio-0.90
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book0.71

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees40
Outstanding Shares14,290,000
Market Cap$45.31

Arsanis (NASDAQ:ASNS) Frequently Asked Questions

What is Arsanis' stock symbol?

Arsanis trades on the NASDAQ under the ticker symbol "ASNS."

How were Arsanis' earnings last quarter?

Arsanis Inc (NASDAQ:ASNS) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.04) by $0.30. View Arsanis' Earnings History.

What price target have analysts set for ASNS?

4 analysts have issued 1-year price targets for Arsanis' stock. Their forecasts range from $23.00 to $27.00. On average, they anticipate Arsanis' stock price to reach $25.3333 in the next twelve months. This suggests a possible upside of 736.1% from the stock's current price. View Analyst Ratings for Arsanis.

What is the consensus analysts' recommendation for Arsanis?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arsanis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Arsanis stock?

Here are some recent quotes from research analysts about Arsanis stock:
  • 1. According to Zacks Investment Research, "Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company's product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. " (7/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "As the company advances its pipeline toward commercialization, we expect catalysts to drive Arsanis’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target." (6/28/2018)

Who are some of Arsanis' key competitors?

Who are Arsanis' key executives?

Arsanis' management team includes the folowing people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 54)
  • Dr. René Russo, Pres, CEO & Director (Age 43)
  • Mr. Michael P. Gray MBA, CPA, COO & CFO (Age 47)
  • Dr. Anthony Christopher Stevens, Chief Medical Officer (Age 59)
  • Dr. Eszter Nagy, Co-Founder (Age 52)

When did Arsanis IPO?

(ASNS) raised $50 million in an initial public offering (IPO) on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.

Has Arsanis been receiving favorable news coverage?

News stories about ASNS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arsanis earned a daily sentiment score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 45.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Arsanis?

Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arsanis' stock price today?

One share of ASNS stock can currently be purchased for approximately $3.03.

How big of a company is Arsanis?

Arsanis has a market capitalization of $45.31 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.

How can I contact Arsanis?

Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]


MarketBeat Community Rating for Arsanis (NASDAQ ASNS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.